RESOURCES

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

Supported by AI-Driven Analysis and Interactive Data Visualization

Learn about GPCR families and their targets. Discover target-specific coupling status and GPCR phylogenetic relationships. Review the available cell-based assay covering >90% of the GPCRome for: cAMP and calcium detection, β-Arrestin recruitment, ligand binding, GTPγS activation, pharmacochaperone discovery, and receptor internalization.

Ion channels are essential targets in drug discovery due to their critical roles in cellular signaling, electrical activity, and homeostasis.

Accelerate Your Drug Discovery with Industry-leading Metabolic Disorder Obesity Solutions

The growing global burden of neurological disorders, driven by aging populations and environmental factors, has renewed interest in this area with a focus on neuroinflammation and neurodegeneration.

Accelerate Timelines and Gather Valuable Data with a Proven and Established Portfolio of Assays and Analytical Tools

Explore Eurofins Discovery’s comprehensive CRO chemistry services, spanning Medicinal, Synthetic, Computational, and Analytical chemistry, from small-scale synthesis to full process development to enable rapid design-make-test-analyze (DMTA) cycles and accelerate your drug discovery programs.

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of small-molecule cytotoxic payloads.

Successful Translational Approach to Accelerate Discovery Programs

Streamline. Automate. Accelerate.

There are numerous drugs withdrawn from the market, assigned warnings or halted in development due to observations of idiosyncratic adverse drug reactions (IADRs).